<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318262</url>
  </required_header>
  <id_info>
    <org_study_id>2018/416/OB</org_study_id>
    <nct_id>NCT04318262</nct_id>
  </id_info>
  <brief_title>Burden of Staphylococcus Lugdunensis Infections in Hospitalized Patients</brief_title>
  <acronym>INHOSTAL</acronym>
  <official_title>Burden of Staphylococcus Lugdunensis Infections in Hospitalized Patients: a Prospective, Bicentric Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Staphylococcus lugdunensis is a coagulase-negative Staphylococcus (CoNS) belonging to the&#xD;
      normal human skin flora. It is responsible for a wide variety of infections, such as skin and&#xD;
      soft tissue infections, bone and joint infections, but also bacteraemia and endocarditis.&#xD;
      Although the implication of S. lugdunensis in infectious diseases is proven, many questions&#xD;
      remain both in terms of clinical and molecular epidemiology.&#xD;
&#xD;
      In this context, INHOSTAL is the first prospective, bicentric study, which will&#xD;
      comprehensively include all patients with S. lugdunensis infection (based on microbiological&#xD;
      and clinical data) in two French university hospitals. The main objective of this study is&#xD;
      thus to determine the incidence of S. lugdunensis infections in hospitalized patients.&#xD;
&#xD;
      Moreover, the originality of this project is to compare the characteristics of S. lugdunensis&#xD;
      infections with those of infections caused by S. aureus and other species of CoNS. Thereby,&#xD;
      the clinical epidemiology of these infections will be compared (i.e. types of infection, mode&#xD;
      of acquisition, host risk factors…).&#xD;
&#xD;
      Finally, complete genome of all S. lugdunensis strains will be sequenced using Illumina&#xD;
      technology and analyzed to describe the molecular epidemiology as well as the molecular&#xD;
      mechanisms of antibiotic resistance (compared to antibiotic susceptibility evaluated by&#xD;
      minimum inhibitory concentrations determined by Sensititre technique). This will enable to&#xD;
      identify if predominant clones exist, and if some strains are spreading into the hospital.&#xD;
&#xD;
      The duration of the study period will be 18 months, to allow the inclusion of a total of 300&#xD;
      patients: 100 S. lugdunensis infections, as well as 100 S. aureus infections and 100 other&#xD;
      species of CoNS infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Staphylococcus lugdunensis infections in hospitalized patients</measure>
    <time_frame>24 months</time_frame>
    <description>Number of patients with S. lugdunensis infection during the study period, relative to the total number of patients hospitalized during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical epidemiology of S. lugdunensis infections compared to that of S. aureus and other CoNS species</measure>
    <time_frame>24 months</time_frame>
    <description>Comparative description of infections:&#xD;
Clinical and biological characteristics&#xD;
Frequency of community- and healthcare-associated infections&#xD;
Antibiotic management and frequency of drainage and surgical procedures&#xD;
Identification of risk factors associated with infections caused by S. lugdunensis, S. aureus and other CoNS species: description of the demographic characteristics, clinical features, history of the disease, and comorbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Current pattern of antibiotic resistance of S. lugdunensis, S. aureus and other CoNS species</measure>
    <time_frame>24 months</time_frame>
    <description>For S. lugdunensis, S. aureus and other CoNS species: resistance rate to major anti-staphylococcal antibiotics according to the determination of MICs by the Sensititre technique&#xD;
For S. lugdunensis: description of the molecular mechanisms of antibiotic resistance from whole genome sequencing data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular epidemiology of S. lugdunensis infections</measure>
    <time_frame>24 months</time_frame>
    <description>Search for epidemic strains of S. lugdunensis in the Normandy region by comparative genomic analysis (high-throughput genome sequencing by Illumina technique)</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Staphylococcus Lugdunensis Infection</condition>
  <arm_group>
    <arm_group_label>Patient with Staphylococcus lugdunensis infection</arm_group_label>
    <description>All consecutive patients with S. lugdunensis infection (microbiological and clinical data)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with Staphylococcus aureus infection</arm_group_label>
    <description>Patients with S. aureus infection (microbiological and clinical data), matched to the hospital sector for S. lugdunensis infections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with other coagulase negative Staphylococcus infection</arm_group_label>
    <description>Patients with CoNS infection (microbiological and clinical data),matched to the hospital sector for S. lugdunensis infections</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Determination of the clinical and biological characteristics</intervention_name>
    <description>clinical data: types of infections (skin and soft tissues, bone and joint, bacteraemia, endocarditis…), delay between clinical signs and hospitalization, number of days of fever, number of days of hospitalization, infectious complications…&#xD;
biological data: Haemoglobin, Leucocytes, Neutrophils, Creatinine clearance, CRP…</description>
    <arm_group_label>Patient with Staphylococcus aureus infection</arm_group_label>
    <arm_group_label>Patient with Staphylococcus lugdunensis infection</arm_group_label>
    <arm_group_label>Patient with other coagulase negative Staphylococcus infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Description of the antibiotic resistance profile</intervention_name>
    <description>Determination of MICs of the major anti-staphylococcal antibiotics by the Sensititre technique</description>
    <arm_group_label>Patient with Staphylococcus aureus infection</arm_group_label>
    <arm_group_label>Patient with Staphylococcus lugdunensis infection</arm_group_label>
    <arm_group_label>Patient with other coagulase negative Staphylococcus infection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Molecular epidemiology of S. lugdunensis infections</intervention_name>
    <description>Genome sequencing (Illumina technique)</description>
    <arm_group_label>Patient with Staphylococcus lugdunensis infection</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Staphylococcus lugdunensis, Staphylococcus aureus or others coagulase negative Staphylococcus&#xD;
      (CoNS) species&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patient with Staphylococcus lugdunensis infection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Hospitalized patients&#xD;
&#xD;
          -  Patients with clinical criteria for infection&#xD;
&#xD;
          -  Patients with at least one of the following microbiological criteria for infection&#xD;
             caused by S. lugdunensis, S. aureus or other CoNS species:&#xD;
&#xD;
          -  Pure culture in a normally sterile site excluding blood culture&#xD;
&#xD;
          -  At least two blood cultures or one blood culture positive and a context of&#xD;
             endocarditis or colonized material (catheter, pace-maker…)&#xD;
&#xD;
          -  Pure or predominant positive culture (probable infection) in a superficial skin sample&#xD;
             taken by swab&#xD;
&#xD;
          -  At least two surgical positive cultures in case of osteo-articular infection&#xD;
&#xD;
          -  Pure positive urine culture (≥104 CFU / mL), in association with abnormal leukocyturia&#xD;
             (≥ 104 / mL)&#xD;
&#xD;
          -  Patients (or trusted person) who have read the information note and who do not oppose&#xD;
             to research participation&#xD;
&#xD;
          -  Patient affiliated to the French Social Security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Patient not affiliated to the French Social Security system&#xD;
&#xD;
          -  Patient with a positive culture for S. lugdunensis, S. aureus or other CoNS species&#xD;
             but who does not meet the inclusion criteria defined above&#xD;
&#xD;
          -  Pulmonary infections of patients with cystic fibrosis&#xD;
&#xD;
          -  Patient already included in the study for an infection caused by S. lugdunensis, S.&#xD;
             aureus or other CoNS species&#xD;
&#xD;
          -  Person deprived of their liberty by an administrative or judicial decision, person&#xD;
             placed under the protection of justice, guardianship or curatorship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine DAHYOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandrine DAHYOT</last_name>
    <phone>+3323288</phone>
    <phone_ext>8265</phone_ext>
    <email>sandrine.dahyot@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BLOT</last_name>
    <phone>+3323288</phone>
    <phone_ext>8265</phone_ext>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe ISNARD, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Christophe ISNARD, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sandrine DAHYOT, Dr</last_name>
      <email>sandrine.dahyot@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Martine PESTEL-CARON, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

